The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's ...

Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's consumer price report. Eli Lilly shares plunged after the pharma giant ...

The U.S. stock market experienced mixed results on Tuesday. The Dow Jones index climbed over 220 points to 42,518.28, while ...

are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make it the S&P 500 index's SPX worst performer.

Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.

S&P 500 edges higher, Nasdaq dips in choppy session as inflation data eyed 12:08 AM UTC Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound ...